Ticker

At a median follow-up of four years, 89.4% recurrence-free rate in patients with tumors ≤3 cm and no prior kidney cancer; 83.9% recurrence-free rate for general study population Full analysis of results to be presented at European Conference of Interventional Oncology 2026 in Basel, Switzerland Data supports broader commercial adoption of ProSense® as a minimally invasive treatment for small renal masses in markets…

Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companies IceCure intends to appoint Dr. Richard Fine as Medical Director CAESAREA, Israel, March 24, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to…

Danaher (NYSE: DHR - Get Free Report) and IceCure Medical (NASDAQ: ICCM - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, institutional ownership, dividends, valuation and risk. Institutional and Insider Ownership 79.1% of Danaher shares are

IceCure Medical (NASDAQ: ICCM) reported record sales for the fourth quarter and full year 2025 and outlined a commercialization strategy centered on its ProSense cryoablation system following recent regulatory and guideline milestones in the U.S. Management highlighted growing interest from hospitals and clinics, progress toward a required U.S. post-marketing study, and ongoing efforts to expand reimbursement

IceCure Medical Ltd (ICCM) Q4 2025 Earnings Call Transcript